S. Montoto, A. Davies, and J. Matthews, Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Journal of Clinical Oncology, vol.25, issue.17, pp.2426-2433, 2007.
DOI : 10.1200/JCO.2006.09.3260

A. Al-tourah, K. Gill, and M. Chhanabhai, Populationbased analysis of incidence and outcome of transformed non- Hodgkin's lymphoma, J Clin Oncol, vol.2616, pp.5165-5169, 2008.

A. Conconi, C. Ponzio, and C. Lobetti-bodoni, Incidence, risk factors and outcome of histological transformation in follicular lymphoma, British Journal of Haematology, vol.13, issue.2, pp.188-196, 2012.
DOI : 10.1111/j.1365-2141.2012.09054.x

N. Wagner-johnston, B. Link, and M. Byrtek, Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS), Blood, vol.126, issue.7, pp.851-857, 2015.
DOI : 10.1182/blood-2015-01-621375

W. Hiddemann, M. Kneba, and M. Dreyling, Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group, Blood, vol.106, issue.12, pp.3725-3732, 2005.
DOI : 10.1182/blood-2005-01-0016

R. Marcus, K. Imrie, and A. Belch, CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma, Blood, vol.105, issue.4, pp.1417-1423, 2005.
DOI : 10.1182/blood-2004-08-3175

M. Herold, A. Haas, and S. Srock, Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study, Journal of Clinical Oncology, vol.25, issue.15, pp.1986-1992, 2007.
DOI : 10.1200/JCO.2006.06.4618

G. Salles, N. Mounier, and S. De-guibert, Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study, Blood, vol.112, issue.13, pp.4824-4831, 2008.
DOI : 10.1182/blood-2008-04-153189

G. Salles, J. Seymour, and F. Offner, Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, The Lancet, vol.377, issue.9759, pp.42-51, 2011.
DOI : 10.1016/S0140-6736(10)62175-7

H. Schouten, High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin???s Lymphoma: Results From the Randomized European CUP Trial, Journal of Clinical Oncology, vol.21, issue.21, pp.3918-3927, 2003.
DOI : 10.1200/JCO.2003.10.023

C. Sebban, P. Brice, and R. Delarue, Impact of Rituximab and/or High-Dose Therapy With Autotransplant at Time of Relapse in Patients With Follicular Lymphoma: A GELA Study, Journal of Clinical Oncology, vol.26, issue.21, pp.3614-3620, 2008.
DOI : 10.1200/JCO.2007.15.5358

M. Ladetto, D. Marco, F. Benedetti, and F. , Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage, Blood, vol.111, issue.8, pp.4004-4013, 2007.
DOI : 10.1182/blood-2007-10-116749

L. Gouill, S. , D. Guibert, S. Planche, and L. , Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study, Haematologica, vol.96, issue.8, pp.1128-1135, 2011.
DOI : 10.3324/haematol.2010.030320

M. Van-oers, R. Klasa, and R. Marcus, Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial, Blood, vol.108, issue.10, pp.3295-3301, 2006.
DOI : 10.1182/blood-2006-05-021113

M. Van-oers, M. Van-glabbeke, and L. Giurgea, Rituximab maintenance treatment of relapsed/resistant follicular non- Hodgkin's lymphoma: long-term outcome of the EORTC, 2010.